Univadis: Apps for Medical News, Medical Education, Medical Resources

HEPATITIS C CHANNEL

Stay ahead on Hepatitis C

Daily summaries of the best new literature
Free access to select articles from Journal of Hepatology, Gastroenterology and NEJM
A vast library of HCV guidelines

Explore the Hepatitis C Channel

ATHEROSCLEROSIS GLOBAL ACADEMY

Get expert knowledge on Atherosclerosis with the
Atherosclerosis Global Academy

- Selected original and review articles from “Atherosclerosis”
- Key opinion leaders’ insights and viewpoints on key topical issues
- Unlimited access to full-text articles

Discover

ELEARNING NOW AVAILABLE

Access exclusive presentations from top medical experts

- Turn your limited free time into valuable learning experiences with concise video summaries by the experts
- Test your knowledge with weekly clinical cases
- Join your peers in the monthly image contest

Access presentations and cases

Kongress Rapporter

HIV-Glasgow 2018 – Fostemsavir (BRIGHTE phase 3 study): 48-week subgroup analysis

Conference Reports
05 november 2018

Dr Peter Ackerman presented the recent results of the BRIGHTE study – an analysis of the prodrug fostemsavir as an attachment inhibitor against HIV. Metabolism to the active moiety temsavir is via the gastrointestinal tract and it has been designed specifically for HIV-1 infected heavily treatment-experienced patients (HTP) who are failing their current therapy. In the BRIGHTE study, 86% of patients coming into the trial had a prior history of AIDS.

HIV-Glasgow 2018 – HIV-associated tuberculosis: diagnosis, management, and prevention

Conference Reports
05 november 2018

Dr Graeme Meintjes presents an overview of diagnostic and prevention issues in adult patients with HIV-associated tuberculosis. Estimates for 2017 showed that approximately 10% of global TB cases occurred in HIV infected people. This group also displays a disproportionately high TB mortality rate. However, incidence rates of HIV-associated TB have declined over the last decade.

HIV-Glasgow 2018 – Ibalizumab phase 3 trial: week 25 and week 48 analysis

Conference Reports
05 november 2018

Dr Zvi Cohen presents the phase 3 trial results of ibalizumab in heavily treatment experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen; ibalizumab was approved by the FDA in March 2018 for this patient population. Results from the Week 25 study (TMB-301) along with the Week 48 expanded access (completer) study (TMB-311) are discussed.

HIV-Glasgow 2018 – MK-8591 efficacy against diverse HIV-1 subtypes and NRTI-resistant clinical isolates

Conference Reports
05 november 2018

Dr Jay Grobler presents the latest data on MK-8591, a novel nucleoside with a unique mechanism of action. This first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI) inhibits HIV replication through multiple mechanisms.

Mer Kongress Rapporter >

Referensportalen för läkare

Mitt konto

Välkommen! Logga in eller skapa ett konto.

HEPATITIS C CHANNEL

Stay ahead on Hepatitis C

ATHEROSCLEROSIS GLOBAL ACADEMY

Get expert knowledge on Atherosclerosis with the
Atherosclerosis Global Academy

ELEARNING NOW AVAILABLE

Access exclusive presentations from top medical experts

Medicinska nyheter

Dabrafenib plus trametinib for biliary tract cancer

European doctors organisation calls for action on alcohol labelling

Google to create artificial intelligence assistant for doctors

Warning over alarming spread of Lyme disease in Europe

Just Published

Huntington’s disease: classification need to be revised for juvenile forms

GBD 2017 study highlights: progress in examining the health-related sustainable development goals (SDG)

Radiology Collection

slide video Epidermoid

slide video Sphenoid Mucocele

slide video Periorbital Cellulitis

slide video Adult Hypoxic Ischemic Injury

slide video Nasopharyngeal Retention Cyst

slide video Carotid Cavernous Fistula

slide video Tethered Cord

slide video Venous Malformations

Kongress Rapporter

HIV-Glasgow 2018 – Fostemsavir (BRIGHTE phase 3 study): 48-week subgroup analysis

HIV-Glasgow 2018 – HIV-associated tuberculosis: diagnosis, management, and prevention

HIV-Glasgow 2018 – Ibalizumab phase 3 trial: week 25 and week 48 analysis

HIV-Glasgow 2018 – MK-8591 efficacy against diverse HIV-1 subtypes and NRTI-resistant clinical isolates

Mitt konto

HEPATITIS C CHANNEL

ATHEROSCLEROSIS GLOBAL ACADEMY

ELEARNING NOW AVAILABLE

Access exclusive presentations from top medical experts

Medicinska nyheter

Just Published

Radiology Collection

Kongress Rapporter

FEATURED CHANNELS

Keep up with oncology literature in minutes, every day

Get your daily dose of the latest evidence published in your cancer area of practice Get my daily Newsletter

Get your daily dose of the latest evidence published in your cancer area of practice
Get my daily Newsletter